- Home
- SUPN vs WGS Comparison
SUPN vs WGS Comparison
Compare SUPN & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- WGS
- Stock Information
- Founded
- SUPN 2005
- WGS 2017
- Country
- SUPN United States
- WGS United States
- Employees
- SUPN N/A
- WGS N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- SUPN Health Care
- WGS Technology
- Exchange
- SUPN Nasdaq
- WGS Nasdaq
- Market Cap
- SUPN 1.7B
- WGS 2.0B
- IPO Year
- SUPN 2012
- WGS N/A
- Fundamental
- Price
- SUPN $32.90
- WGS $100.80
- Analyst Decision
- SUPN Hold
- WGS Strong Buy
- Analyst Count
- SUPN 2
- WGS 5
- Target Price
- SUPN $36.00
- WGS $82.60
- AVG Volume (30 Days)
- SUPN 787.3K
- WGS 745.2K
- Earning Date
- SUPN 05-07-2025
- WGS 04-28-2025
- Dividend Yield
- SUPN N/A
- WGS N/A
- EPS Growth
- SUPN 6500.00
- WGS N/A
- EPS
- SUPN 1.32
- WGS N/A
- Revenue
- SUPN $661,817,000.00
- WGS $305,450,000.00
- Revenue This Year
- SUPN N/A
- WGS $18.58
- Revenue Next Year
- SUPN $8.67
- WGS $17.65
- P/E Ratio
- SUPN $24.90
- WGS N/A
- Revenue Growth
- SUPN 8.94
- WGS 50.79
- 52 Week Low
- SUPN $25.53
- WGS $8.10
- 52 Week High
- SUPN $40.28
- WGS $115.60
- Technical
- Relative Strength Index (RSI)
- SUPN 46.17
- WGS 58.60
- Support Level
- SUPN $31.69
- WGS $93.40
- Resistance Level
- SUPN $32.90
- WGS $107.98
- Average True Range (ATR)
- SUPN 0.96
- WGS 7.20
- MACD
- SUPN 0.29
- WGS 0.39
- Stochastic Oscillator
- SUPN 89.25
- WGS 82.91
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.